BrainChip (BRN) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
29 Jul, 2025Executive summary
Cash balance of US$13.5M at quarter-end, providing sufficient capital for growth and R&D investment.
Board decided to remain listed on the ASX after evaluating redomiciling options.
Commercial partnerships expanded, including collaborations with Arquimea, Andes Technology, Chelpis Quantum, Frontgrade Gaisler, and HaiLa Technologies.
Launched MetaTF 2.13 software and a new Developer Hub to accelerate edge AI innovation.
Financial highlights
Cash inflow from customers was US$1.4M, up from US$0.14M in the prior quarter.
Net operating cash outflows were US$2.8M, an improvement from US$4.1M in the previous quarter.
Total payments to suppliers and employees were US$4.4M, down from US$4.9M sequentially.
Ended the quarter with US$13.5M in cash, compared to US$16.95M in the prior quarter.
Estimated 4.96 quarters of funding available based on current cash burn.
Outlook and guidance
Management reaffirmed commitment to long-term value creation and scaling the product portfolio.
Focus remains on developing key customer and partner relationships to drive revenue growth.
Latest events from BrainChip
- Revenue up 374%, net loss reduced, and $37M raised to accelerate neuromorphic AI growth.BRN
H2 202526 Feb 2026 - Revenue up 72% and net loss reduced, with strong capital raises and key commercial wins.BRN
H2 202420 Feb 2026 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 202529 Jan 2026 - Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.BRN
Q3 20251 Dec 2025 - A pivotal year with a new product roadmap, higher bookings targets, and focus on shareholder alignment.BRN
AGM 202520 Nov 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation10 Nov 2025 - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation19 Oct 2025 - Revenue soared 859% and net loss narrowed, with new funding and partnerships fueling growth.BRN
H1 202521 Aug 2025 - Cash position strengthened to US$25.6M, supporting commercialization and product development.BRN
Q3 202413 Jun 2025